UNIQURE AMT-130

Reclutando

ACERCA DE

PATROCINADOR

UniQure Biopharma B.V.

PARTICIPANTES

26

El ensayo clínico europeo de fase Ib/II de AMT-130 para el tratamiento de la EH explorará la seguridad y la prueba de concepto (evidencia del proyecto piloto) en 15 pacientes con enfermedad de Huntington de manifestación temprana. El candidato a producto de terapia génica AMT-130 consiste en un vector AAV5 que lleva un micro-ARN artificial específicamente adaptado para silenciar el gen de la huntingtina.

El vector está inactivo y es sólo un vehículo para administrar el fármaco. Se trata de una inyección única directamente en el cerebro. El ensayo se denomina «abierto», por lo que los participantes saben lo que están recibiendo. Hay dos dosis, una baja y otra alta. 

Ricardo Dolmetsch presenta las actualizaciones del AMT-130

Edades elegibles
para el estudio:

De 25 años a 65 años

(adulto, adulto mayor)

Sexos elegibles
para el estudio:

Todos

Acepta voluntarios sanos:

No

Criterios de inclusión:

  • EH manifiesta temprana definida por una puntuación de capacidad funcional total (TFC) de la UHDRS de 9 a 13, o bien un nivel de clasificación diagnóstica (DCL) de 4, o un DCL de 3 si el sujeto cumple la definición de EH manifiesta multidimensional (pregunta 80 de la UHDRS) o tiene síntomas cognitivos.
  • Prueba de expansión del gen HTT con la presencia de ≥40 repeticiones CAG.
  • Requerimientos de volumen de resonancia magnética estriatal por hemisferio: Putamen ≥2,5 cm3 (por lado); Caudado ≥2,0 cm3 (por lado)
  • Todas las medicaciones concomitantes de la EH (que aborden los síntomas motores, conductuales y cognitivos) estables durante los 3 meses anteriores a la selección.
  • Capaz y dispuesto a dar su consentimiento informado por escrito
  • Capaz y dispuesto a cumplir con todos los procedimientos y visitas del estudio

Criterios de exclusión:

  • Evidencia de riesgo de suicidio
  • Recepción de un agente experimental dentro de los 60 días o cinco semividas anteriores a la Selección o en cualquier momento durante la duración de este estudio.
  • Participación en un ensayo de investigación o paradigma de investigación (como ejercicio/actividad física, terapia cognitiva, estimulación cerebral, etc.) en los 60 días anteriores a la selección o en cualquier momento durante la duración de este estudio.
  • Presencia de un dispositivo de estimulación cerebral profunda implantado, derivación ventriculoperitoneal u otra derivación de LCR, u otro catéter implantado
    Cualquier antecedente de terapia génica, ARN o ADN dirigido a agentes específicos de la EH, como oligonucleótidos antisentido (ASO), trasplante de células o cualquier otra cirugía cerebral experimental.
  • Cualquier contraindicación a la punción lumbar o a la resonancia magnética de 3,0 Tesla según las directrices locales.
    Patología cerebral y espinal que pueda interferir con la administración quirúrgica de AMT-130 o que represente un trastorno neurológico comórbido significativo.
  • Hospitalización por cualquier procedimiento médico o quirúrgico importante que implique anestesia general dentro de las 12 semanas anteriores a la selección o planificada durante el estudio.
  • Enfermedad actual o recurrente, infección u otra condición médica concurrente significativa o medicamentos que puedan confundir las evaluaciones clínicas y de laboratorio o que puedan afectar la seguridad del sujeto o su capacidad para someterse al procedimiento neuroquirúrgico o cumplir con los procedimientos y el programa de visitas del estudio.

PAÍSES

POLONIA

  • TRIAL SITE: Instytut Psychiatrii I Neurologii
  • Address: Warsaw, Poland, 02-957
  • Principal Investigator: Grzegorz Witkowski, MD, PhD

OTROS LUGARES EN AMÉRICA

new FB feed (19)

dictionary:

SNP-single nucleotide polymorphisms

a single-letter spelling difference in a gene. SNPs, pronounced ‘snips’, are common and most don’t change the function of the gene.

 
new FB feed (19)

dictionary:

at risk

You do not know if you carry the genetic mutation for HD gene 

 
new FB feed (19)

dictionary:

TFC-total functional capacity

A standardized rating scale for function in HD, used to assess capacity to work, handle finances, perform domestic chores and self-care tasks.
Scores range from 0 to 13, with higher scores indicating better functional capacity. 

 
new FB feed (19)

dictionary:

Double-blinded

 means that neither the participant nor the clinical trial doctor can choose or know the group the participant is in until the trial is over. This approach helps to prevent bias.

new FB feed (19)

dictionary:

Open label

A trial in which the patient and doctor know what drug is being used. Open label trials are susceptible to bias through placebo effects.

new FB feed (19)

dictionary:

Gene therapy

a technique that aims to treat or prevent diseases by modifying a person’s genes. It involves introducing, removing, or changing genetic material (DNA or RNA) within a patient’s cells.

new FB feed (19)

dictionary:

UHDRS- Unified Huntington Disease Rating Scale

A standardized neurological examination that aims to provide a uniform assessment of the clinical features of HD

new FB feed (19)

dictionary:

CAG repeat

The stretch of DNA at the beginning of the HD gene, which contains the sequence CAG repeated many times, and is abnormally long in people who will develop HD

new FB feed (19)

dictionary:

Wild-type

the opposite of ‘mutant’. Wild-type huntingtin, for example, is the ‘normal’, ‘healthy’ protein

new FB feed (19)

dictionary:

Tolerabilty

How well a person can handle a treatment without having serious or uncomfortable side effects.

new FB feed (19)

dictionary:

Striatum

Part of the brain that  coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward system.

new FB feed (19)

dictionary:

Randomized allocation

A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.

new FB feed (19)

dictionary:

Radioligand

a radioactive substance that binds to a specific target in the body, allowing visualization of that target’s distribution and activity

new FB feed (19)

dictionary:

Protein

Protein builds, maintains, and replaces the tissues in your body. The building blocks of life.

new FB feed (19)

dictionary:

Premanifest / Prodromal

Prior to onset or diagnosis of movement symptoms.

new FB feed (19)

dictionary:

Placebo

A placebo is a dummy medicine containing no active ingredients. The placebo effect is a psychological effect that causes people to feel better even if they’re taking a pill that doesn’t work.

new FB feed (19)

dictionary:

PK - Pharmacokinetics

The movement of drugs through the body

new FB feed (19)

dictionary:

PD - Pharmacodynamics

The body’s biological response to drugs

new FB feed (19)

dictionary:

PET scan

Positron emission tomography which produces detailed 3-dimensional images of the inside of the body.

new FB feed (19)

dictionary:

Neuron

Brain cells that store and transmit information

new FB feed (19)

dictionary:

MRI

Magentic resonance imaging: A technique using powerful magnetic fields to produce detailed images and visualizes the structure of organs, tissues, and bones 

new FB feed (19)

dictionary:

mHTT

Mutant huntingtin protein. The protein produced by the faulty HD gene.

new FB feed (19)

dictionary:

Manifest

after HD diagnosis, or when symptoms are already showing

new FB feed (19)

dictionary:

Longitudinal study

A study where each participant is looked at several times over a time period – unlike a cross-sectional study, where each participant is looked at only once

new FB feed (19)

dictionary:

HTT

one abbreviation for the gene that causes Huntington’s disease. The same gene is also called HD and IT-15

new FB feed (19)

dictionary:

fMRI

functional MRI:As with MRI, a technique using powerful magnetic fields  but focusing on brain function by measuring and mapping changes in blood flow, revealing which areas of the brain are active during specific tasks or cognitive processes

new FB feed (19)

dictionary:

CSF - cerebrospinal fluid

A clear fluid produced by the brain, which surrounds and supports the brain and spinal cord.

new FB feed (19)

dictionary:

Efficacy

A measure of whether a treatment works or not

new FB feed (19)

dictionary:

ASO(Antisense oligonucleotides)

A type of gene silencing treatment in which specially designed DNA molecules are used to switch off a gene

new FB feed (19)

dictionary:

Biomarker

a test of any kind – including blood tests, thinking tests and brain scans – that can measure or predict the progression of a disease like HD. Biomarkers may make clinical trials of new drugs quicker and more reliable

new FB feed (19)

dictionary:

BDNF

Brain-derived neurotrophic factor: a growth factor that may be able to protect neurons in HD.

new FB feed (19)

dictionary:

Allele

one of the two copies of a gene

new FB feed (19)

dictionary:

Plasma

Liquid component of the blood.

new FB feed (19)

dictionary:

Gene

The basic unit of heredity passed from parent to child. Genes are made up of sequences of DNA and are arranged, one after another, at specific locations on chromosomes in the nucleus of cells.

new FB feed (19)

dictionary:

Phase

Clinical trial phases are different stages of research that assess the safety and effectiveness of a new medical treatment or intervention in humans.

Each phase has a specific goal and involves a different number of participants. Generally, there are 4 phases (I-IV), with Phase I focusing on safety and dosage, Phase II on efficacy and side effects, Phase III on comparing the new treatment with standard treatments, and Phase IV on long-term safety monitoring.